SingleStrand Biotech is a biotechnology company pioneering the development of synthetic single-stranded oligonucleotide (ODN) drugs that modulate the immune system and promote tissue regeneration. Our focus is on delivering next-generation therapies for chronic inflammatory diseases—starting with Crohn’s Disease—through innovative, precise, and long-lasting solutions.
Founded by leading researchers and supported by an experienced advisory board, SingleStrand Biotech merges academic excellence with entrepreneurial drive. With over two decades of experience in ODN research, our team has designed a platform that redefines how we approach immune modulation.
Founders
 | CEO – Alejandro Montaner PhD 2nd time founder. Advisor to local pharmaceutical companies. Strong entrepreneurial profile. 20 years of experience in R&D on ODNs. Researcher (CONICET) Incubation of SSBio: CBL (FBCB-UNL)  |
 | CTO: Eduardo Mufarrege PhD Researcher (CONICET). Professor of Immunology (FBCB-UNL). Post-doc at FDA. Extensive experience in applied research in cutting-edge biopharmaceuticals. Incubation of SSBio: CBL (FBCB-UNL) |